Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâ€™s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

23/06	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
30/04	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI

Market Cap	12Cr 14Cr 11Cr 10Cr 20Cr 1.33TCr 20Cr 134.72Cr 52Cr 653.74Cr 52Cr 51Cr 2.25TCr	P/E 2026 *	-5.02x	P/E 2027 *	-5.2x
Enterprise Value	11Cr 13Cr 10Cr 9.78Cr 19Cr 1.24TCr 19Cr 125.97Cr 49Cr 611.29Cr 49Cr 48Cr 2.11TCr	EV / Sales 2026 *	9.97x	EV / Sales 2027 *	5.3x
Free-Float	21.17%	Yield 2026 *	-	Yield 2027 *	-

23/06	Heidelberg Pharma Ag Approves the Election of Mr. Jack Yefei Ling as New Member of the Supervisory Board	CI
30/04	Heidelberg Pharma AG Reports Earnings Results for the First Quarter Ended February 28, 2026	CI
17/04	Heidelberg Pharma AG Announces Chief Financial Officer Changes	CI
09/04	Heidelberg Pharma Sets Dose for Mid-stage Trial of Multiple Myeloma Drug Candidate	MT
09/04	Heidelberg Pharma AG Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101	CI
04/04	Heidelberg Pharma AG Presents Data from Its ADC Technology Platform At AACR Annual Meeting	CI
31/03	Heidelberg Pharma AG, 2025 Earnings Call, Mar 26, 2026
26/03	Heidelberg Pharma AG Reports Earnings Results for the Full Year Ended November 30, 2025	CI
26/03	Heidelberg Pharma AG Provides Earnings Guidance for the Fiscal Year 2026	CI
18/03	Heidelberg Pharma Set to Get Milestone Payment for Plasma Cell Disorders Treatment Clinical Study	MT
18/03	Heidelberg Pharma AG Receives Milestone Payment for Clinical Study with HDP-101 in China	CI
07/03	Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement	RE
25/11	Heidelberg Pharma Names New CEO	MT

23/06	Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026	EQ
13/05	Heidelberg Pharma : Explanations on the resolutionless agenda item 1 (HDP ExplanationItem1)	PU
13/05	Heidelberg Pharma : CV of the proposed Supervisory Board candidate (202605 CV AR 2026 engl)	PU
13/05	Heidelberg Pharma : Articles of Association (20260121 HeidelbergPharma ArticlesAssociation)	PU
13/05	Heidelberg Pharma : Explanation of shareholders' rights (HDP explanations of the rights of shareholders copy 2)	PU

23/06	Heidelberg Pharma : Voting results (HPHA Abstimmung Liste copy 1)
23/06	Heidelberg Pharma : Abstimmungsergebnisse (HPHA Abstimmung Liste)
23/06	Heidelberg Pharma berichtet über die Ergebnisse der ordentlichen Hauptversammlung 2026
19/06	Kalender der Dividendenausschüttungen und Hauptversammlungen vom 22. bis 26. Juni 2026
15/05	HV: Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Wilex AG Share Price Xetra

Stocks

DE0006614720

Biotechnology & Medical Research

Valuation: Wilex AG

Latest news : Wilex AG

Last Transcript: Wilex AG

Analysts' recommendations: Wilex AG

Press Releases: Wilex AG

News in other languages: Wilex AG

Managers and Directors: Wilex AG

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Dong Zhou Liu CEO	Chief Executive Officer	-	24/11/2025
Peter Willinger DFI	Director of Finance/CFO	-	01/05/2026
András Strassz CTO	Chief Tech/Sci/R&D Officer	-	01/03/2021

Director	Title	Age	Since
Georg F. Baur CHM	Chairman	76	14/12/2000
Birgit Kudlek BRD	Director/Board Member	59	25/05/2012
Mathias Hothum BRD	Director/Board Member	58	30/07/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	5.91TCr
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	5.52TCr
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	2.47TCr
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	2.42TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	1.97TCr
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	1.76TCr
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	1.62TCr
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	1.4TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	1.48TCr
Average	+2.87%	+8.57%	+54.64%	+148.04%	2.73TCr
Weighted average by Cap.	+2.46%	+6.47%	+59.06%	+137.71%

	2026 *	2027 *
Net sales	1.14Cr 1.31Cr 1.05Cr 98.08L 1.86Cr 124.71Cr 1.89Cr 13Cr 4.91Cr 61Cr 4.92Cr 4.81Cr 211.24Cr	1.98Cr 2.26Cr 1.82Cr 1.7Cr 3.22Cr 215.65Cr 3.27Cr 22Cr 8.49Cr 106Cr 8.5Cr 8.32Cr 365.29Cr
Net income	-2.43Cr -2.78Cr -2.23Cr -2.08Cr -3.95Cr -264.67Cr -4.01Cr -27Cr -10Cr -130.1Cr -10Cr -10Cr -448.3Cr	-2.35Cr -2.69Cr -2.16Cr -2.01Cr -3.82Cr -255.95Cr -3.88Cr -26Cr -10Cr -125.81Cr -10Cr -9.87Cr -433.55Cr
Net Debt	-79.28L -90.69L -72.86L -67.92L -1.29Cr -86Cr -1.31Cr -8.75Cr -3.4Cr -42Cr -3.4Cr -3.33Cr -146.27Cr	-1.72Cr -1.97Cr -1.58Cr -1.48Cr -2.8Cr -187.72Cr -2.84Cr -19Cr -7.39Cr -92Cr -7.4Cr -7.24Cr -317.96Cr

End-of-day quote Xetra Other stock markets
- ^EUR	-